Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus' Safety Switch System in Cell Therapies for Autoimmune Disease

(marketscreener.com) LONDON, Jan. 09, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc . The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety...https://www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Announces-Collaboration-with-Cabaletta-Bio-for-Use-of-Autolus-Safety-Switch-Sy-42691472/?utm_medium=RSS&utm_content=20230109